INKT Logo

MiNK Therapeutics, Inc. (INKT) 

NASDAQ
Market Cap
$28.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
579 of 776
Rank in Industry
314 of 433

Largest Insider Buys in Sector

INKT Stock Price History Chart

INKT Stock Performance

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based …

Insider Activity of MiNK Therapeutics, Inc.

Over the last 12 months, insiders at MiNK Therapeutics, Inc. have bought $0 and sold $0 worth of MiNK Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at MiNK Therapeutics, Inc. have bought $5.86M and sold $94,850 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 429 shares for transaction amount of $472 was made by AGENUS INC (10 percent owner) on 2023‑10‑16.

List of Insider Buy and Sell Transactions, MiNK Therapeutics, Inc.

2023-10-16Purchase10 percent owner
429
0.0012%
$1.10$472-15.45%
2023-10-13Purchase10 percent owner
19,373
0.0561%
$1.10$21,310-15.45%
2023-10-12Purchase10 percent owner
3,173
0.0089%
$1.10$3,488-18.41%
2023-10-04Purchase10 percent owner
15,001
0.0465%
$1.09$16,380-17.59%
2023-08-29Purchase10 percent owner
29,678
0.0826%
$1.52$45,016-38.68%
2023-08-28Purchase10 percent owner
12,808
0.0371%
$1.45$18,570-33.00%
2023-08-24Purchase10 percent owner
170,244
0.4482%
$1.54$262,908-37.33%
2023-05-11Purchase10 percent owner
23,361
0.0606%
$1.43$33,348-34.57%
2023-05-10Purchase10 percent owner
22,065
0.0649%
$1.51$33,296-29.80%
2023-05-05Saledirector
100,000
0.1767%
$0.95$94,850-31.96%
2023-05-05Purchase10 percent owner
100,200
0.1772%
$0.95$95,100-31.96%
2023-05-05Purchase10 percent owner
200
0.0005%
$1.25$250-31.96%
2023-05-04Purchase10 percent owner
21,473
0.0618%
$1.22$26,246-13.80%
2023-05-03Purchase10 percent owner
128,689
0.3494%
$1.08$138,843-7.69%
2023-05-02Purchasedirector
100,000
0.3138%
$0.95$94,850+21.35%
2022-07-18Purchase
3,339
0.0098%
$1.33$4,438+60.45%
2021-10-19Purchase10 percent owner
1.4M
4.2248%
$12.00$16.8M-79.46%

Insider Historical Profitability

<0.0001%
AGENUS INC10 percent owner
21772863
55.0658%
$0.73140<0.0001%
ARMEN GARO Hdirector
1866400
4.7203%
$0.7311+21.35%
WIINBERG ULF
281639
0.7123%
$0.7310+60.45%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$212,708.000.6234,1820%+$0<0.0001
Longbow Finance Sa$151,383.000.42166,6660%+$00.02
Renaissance Technologies$96,000.000.27105,228+14.33%+$12,030.56<0.0001
Geode Capital Management$80,727.000.2388,856-1.45%-$1,188.34<0.0001
BlackRock$69,165.000.1976,148-0.4%-$280.66<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.